# A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

> **NCT06643377** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 27 (actual)

## Conditions studied

- Healthy
- Renal Impairment

## Interventions

- **DRUG:** Enlicitide

## Key facts

- **NCT ID:** NCT06643377
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-22
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643377, "A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06643377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*